Figure 2

Prostate Cancer Biomarker Panel Performs Better Than PSA Alone in Differentiating Patients with Lower Urinary Tract Symptoms (LUTS) or Benign Prostate Hyperplasia (BPH) from Prostate Cancer (PCa). (A) Beeswarm and boxplot graphs showing median, interquartile range and distribution of age (years), prostate volume (mL), serum FLNA concentrations (pg/mL), and serum PSA concentrations (ng/mL) from patients with LUTS/BPH compared to those with PCa. Data represents n = 300 LUTS/BPH and n = 477 PCa. (B) Receiver operator characteristics (ROC) curve for prostate cancer biomarker panel demonstrates better performance in differentiating patients with LUTS/BPH from PCa compared to PSA alone. Area under the curve (AUC) for the panel is 0.75 versus PSA alone 0.55. Shaded grey regions indicate standard error.